{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:06Z","timestamp":1791999906032,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100347","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:04:29Z","timestamp":1781967869000},"page":"100347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A protein standard addition framework for absolute quantification of drug metabolizing enzymes"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-2163","authenticated-orcid":false,"given":"Xiaofeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2094-0943","authenticated-orcid":false,"given":"Sam","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-3264","authenticated-orcid":false,"given":"Qianying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-5379","authenticated-orcid":false,"given":"Kimberly","family":"Lapham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-1767","authenticated-orcid":false,"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-4397","authenticated-orcid":false,"given":"Lloyd Wei Tat","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmd.2026.100347_bib1","first-page":"687","article-title":"Abundance of cytochromes P450 in human liver: a meta-analysis","volume":"57","author":"Yeo","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100347_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100347_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \"pie\"","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100347_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/abbi.1998.0615","article-title":"Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations","volume":"353","author":"Lasker","year":"1998","journal-title":"Arch Biochem Biophys"},{"issue":"7","key":"10.1016\/j.dmd.2026.100347_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.106.106013","article-title":"Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism","volume":"318","author":"Galetin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100347_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.mie.2016.10.002","article-title":"Label-free and standard-free absolute quantitative proteomics using the \"total protein\" and \"proteomic ruler\" approaches","volume":"585","author":"Wisniewski","year":"2017","journal-title":"Methods Enzymol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acs.molpharmaceut.2c00950","article-title":"Quantitative characterization of clinically relevant drug-metabolizing enzymes and transporters in rat liver and intestinal segments for applications in PBPK modeling","volume":"20","author":"Sharma","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2026.100347_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpba.2014.08.016","article-title":"Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics","volume":"100","author":"Groer","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt.967","article-title":"Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens","volume":"104","author":"Drozdzik","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100347_bib11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3390\/ph18121789","article-title":"Protein levels of 16 cytochrome P450s and 2 carboxyl esterases using absolute quantitative proteomics: CYP2C9 and CYP3A4 are the most abundant isoforms in human liver and intestine, respectively","volume":"18","author":"Grangeon","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1016\/j.dmd.2026.100347_bib12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1074\/mcp.M600456-MCP200","article-title":"Absolute multiplexed quantitative analysis of protein expression during muscle development using QconCAT","volume":"6","author":"Rivers","year":"2007","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"10.1016\/j.dmd.2026.100347_bib13","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1021\/pr400279u","article-title":"Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters","volume":"12","author":"Russell","year":"2013","journal-title":"J Proteome Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100048","article-title":"Efficient protein quantification in drug metabolism and pharmacokinetics with an accelerated proteomic workflow","volume":"53","author":"Wu","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100347_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100217","article-title":"A unified methodology enabling simultaneous measurements of CYP3A4 mRNA, protein, and activity induction responses in human hepatocytes","volume":"54","author":"Wu","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/molpharm.121.000256","article-title":"Differential reversible and irreversible interactions between benzbromarone and human cytochrome P450s 3A4 and 3A5","volume":"100","author":"Tang","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100347_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100277","article-title":"Mass spectrometry imaging uncovers drug-induced lipid alterations in the mouse heart","volume":"54","author":"Jayasekera","year":"2026","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100347_bib18","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/jps.24506","article-title":"Plasma protein binding of challenging compounds","volume":"104","author":"Riccardi","year":"2015","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100347_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cpt.3643","article-title":"Hepatic impairment and the differential effects on drug clearance mechanisms: analysis of pharmacokinetic changes in disease state","volume":"118","author":"Tang","year":"2025","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:58Z","timestamp":1791996778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006161"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100347","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A protein standard addition framework for absolute quantification of drug metabolizing enzymes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100347"}}